Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,656JPY
14 Dec 2018
Change (% chg)

¥-34 (-2.04%)
Prev Close
¥1,690
Open
¥1,690
Day's High
¥1,716
Day's Low
¥1,656
Volume
10,216,400
Avg. Vol
6,830,659
52-wk High
¥2,056
52-wk Low
¥1,380

Chart for

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea, Taiwan and other markets through its subsidiaries. Its main... (more)

Overall

Beta: 0.60
Market Cap(Mil.): ¥3,012,207.00
Shares Outstanding(Mil.): 2,068.82
Dividend: 18.00
Yield (%): 2.34

Financials

  4503.T Industry Sector
P/E (TTM): 15.71 31.13 34.39
EPS (TTM): 92.68 -- --
ROI: 13.91 15.55 14.96
ROE: 15.50 16.92 16.52

Swiss stocks - Factors to watch on Dec 10

ZURICH/BERLIN, Dec 10 The Swiss blue-chip SMI was seen opening 0.9 percent lower at 8,659 points on Monday, according to premarket indications by bank Julius Baer .

Dec 10 2018

Astellas Pharma gets U.S. nod for blood cancer treatment

The U.S. Food and Drug Administration on Wednesday approved a blood cancer treatment from Japan's Astellas Pharma Inc, making it the first targeted therapy to treat patients with a certain mutation.

Nov 28 2018

UPDATE 2-Astellas Pharma gets U.S. nod for blood cancer treatment

Nov 28 The U.S. Food and Drug Administration on Wednesday approved a blood cancer treatment from Japan's Astellas Pharma Inc, making it the first targeted therapy to treat patients with a certain mutation.

Nov 28 2018

Astellas Pharma gets U.S. nod for blood cancer treatment

Nov 28 Japan's Astellas Pharma Inc on Wednesday received approval from the U.S. Food and Drug Administration for its blood cancer treatment, according to the regulator's website https://bit.ly/2SjB8CL.

Nov 28 2018

Pfizer, Astellas revise two cancer drug trial protocols to speed up results

Drugmakers Pfizer Inc and Astellas Pharma Inc said on Wednesday they would change protocols for two late-stage trials testing prostate cancer drug Xtandi to speed up completion.

Aug 22 2018

Pfizer, Astellas revise two cancer drug trial protocols to speed up results

Aug 22 Drugmakers Pfizer Inc and Astellas Pharma Inc said on Wednesday they would change protocols for two late-stage trials testing prostate cancer drug Xtandi to speed up completion.

Aug 22 2018

Earnings vs. Estimates